BREZTRI AEROSPHERE (budesonide, glycopyrrolate, and formoterol fumarate) by AstraZeneca is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 2020.
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
BREZTRI AEROSPHERE is a triple-combination inhaled corticosteroid (budesonide), long-acting muscarinic antagonist (glycopyrrolate), and long-acting beta-2 agonist (formoterol fumarate) approved for maintenance treatment of COPD. It works by reducing airway inflammation, improving airflow, and decreasing mucus production. The product combines three distinct pharmacologic mechanisms in a single metered-dose aerosol formulation.
Strong commercial phase with $796M in Part D spending (2023) and nearly 1M patient claims indicates a well-established franchise with significant team infrastructure supporting commercial execution.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
Worked on BREZTRI AEROSPHERE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
$796M Medicare spend — this is a commercially significant brand
BREZTRI supports a substantial 1,215-person job pipeline dominated by commercial field roles (Medical Representatives, Area Managers) and Medical Affairs positions (MSLs, Medical Directors). Working on this product offers exposure to large-scale patient populations, established primary care networks, and complex payer/reimbursement negotiations in a peak-revenue phase franchise.
1215 open roles linked to this drug
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo